Mesoblast (MESO) Cash & Equivalents (2015 - 2025)

Mesoblast has disclosed Cash & Equivalents across 11 years of filings, most recently posting $130.0 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $130.0 million, up 241.78% year-over-year; the trailing twelve-month figure through Dec 2025 was $130.0 million (up 241.78% YoY), and the FY2025 annual result was $161.6 million, up 156.59% from the prior year.
• Cash & Equivalents came in at $130.0 million for Q4 2025 at Mesoblast, down from $161.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $161.6 million in Q2 2025 to a low of $38.0 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $77.6 million (2023), against an average of $92.4 million.
• Across the five-year window, Cash & Equivalents sank 55.84% in 2022 and jumped 241.78% in 2025, its largest moves.
• Mesoblast's Cash & Equivalents stood at $94.8 million in 2021, then declined by 28.71% to $67.6 million in 2022, then gained by 14.69% to $77.6 million in 2023, then tumbled by 50.96% to $38.0 million in 2024, then surged by 241.78% to $130.0 million in 2025.
• The last three Cash & Equivalents figures came in at $130.0 million (Q4 2025), $161.6 million (Q2 2025), and $38.0 million (Q4 2024), per Business Quant data.